IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2017 Mar 22

PMID 28321215

Citations 8

Authors

Xu Wang

He Wang

Man-Qing Liu

Jie-Liang Li

Run-Hong Zhou

Yu Zhou

Yi-Zhong Wang

Wang Zhou

Wen-Zhe Ho

Affiliations

Soon will be listed here.

Abstract

Type III interferons (IFN-λs) have been demonstrated to inhibit a number of viruses, including HIV. Here, we further examined the anti-HIV effect of IFN-λs in macrophages. We found that IFN-λs synergistically enhanced anti-HIV activity of antiretrovirals [azidothymidine (AZT), efavirenz, indinavir, and enfuvirtide] in infected macrophages. Importantly, IFN-λs could suppress HIV infection of macrophages with the drug-resistant strains, including AZT-resistant virus (A012) and reverse transcriptase inhibitor-resistant virus (TC49). Mechanistically, IFN-λs were able to induce the expression of several important anti-HIV cellular factors, including myxovirus resistance 2 (Mx2), a newly identified HIV post-entry inhibitor and tetherin, a restriction factor that blocks HIV release from infected cells. These observations provide additional evidence to support the potential use of IFN-λs as therapeutics agents for the treatment of HIV infection.

Citing Articles

Current drugs for HIV-1: from challenges to potential in HIV/AIDS.

Peng Y, Zong Y, Wang D, Chen J, Chen Z, Peng F Front Pharmacol. 2023; 14:1294966.

PMID: 37954841 PMC: 10637376. DOI: 10.3389/fphar.2023.1294966.

The Landscape of IFN/ISG Signaling in HIV-1-Infected Macrophages and Its Possible Role in the HIV-1 Latency.

Rojas M, Luz-Crawford P, Soto-Rifo R, Reyes-Cerpa S, Toro-Ascuy D Cells. 2021; 10(9).

PMID: 34572027 PMC: 8467246. DOI: 10.3390/cells10092378.

HIV replication and latency in monocytes and macrophages.

Veenhuis R, Abreu C, Shirk E, Gama L, Clements J Semin Immunol. 2021; 51:101472.

PMID: 33648815 PMC: 10171083. DOI: 10.1016/j.smim.2021.101472.

Increased Expression on Innate Immune Factors in Placentas From HIV-Infected Mothers Concurs With Dampened Systemic Immune Activation.

Pereira N, Castelo Branco A, Manfrere K, de Lima J, Yoshikawa F, Milanez H Front Immunol. 2020; 11:1822.

PMID: 32983090 PMC: 7477039. DOI: 10.3389/fimmu.2020.01822.

The Role of Macrophages in HIV-1 Persistence and Pathogenesis.

Kruize Z, Kootstra N Front Microbiol. 2019; 10:2828.

PMID: 31866988 PMC: 6906147. DOI: 10.3389/fmicb.2019.02828.

References

Wainberg M, Turner D . Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr. 2004; 37 Suppl 1:S36-43. DOI: 10.1097/01.qai.0000137005.63376.6e. View

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore T . IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2002; 4(1):63-8. DOI: 10.1038/ni873. View

BERGER E, Doms R, Fenyo E, Korber B, Littman D, Moore J . A new classification for HIV-1. Nature. 1998; 391(6664):240. DOI: 10.1038/34571. View

Zhou Y, Wang X, Liu M, Hu Q, Song L, Ye L . A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology. 2010; 131(1):40-9. PMC: 2966756. DOI: 10.1111/j.1365-2567.2010.03270.x. View

Lasfar A, Abushahba W, Balan M, Cohen-Solal K . Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol. 2011; 2011:349575. PMC: 3235441. DOI: 10.1155/2011/349575. View

Neil S, Zang T, Bieniasz P . Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177):425-30. DOI: 10.1038/nature06553. View

Palma-Ocampo H, Flores-Alonso J, Vallejo-Ruiz V, Reyes-Leyva J, Flores-Mendoza L, Herrera-Camacho I . Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J. 2015; 12:150. PMC: 4584467. DOI: 10.1186/s12985-015-0383-4. View

Ho W, Lioy J, Song L, Cutilli J, Polin R, Douglas S . Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. J Virol. 1992; 66(1):573-9. PMC: 238319. DOI: 10.1128/JVI.66.1.573-579.1992. View

Ank N, Paludan S . Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors. 2009; 35(1):82-7. DOI: 10.1002/biof.19. View

10.

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

11.

Guenterberg K, Grignol V, Raig E, Zimmerer J, Chan A, Blaskovits F . Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther. 2010; 9(2):510-20. PMC: 2820597. DOI: 10.1158/1535-7163.MCT-09-0461. View

12.

Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J . Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. J Interferon Cytokine Res. 2016; 36(11):635-643. DOI: 10.1089/jir.2015.0173. View

13.

Zhang H, Yang B, Pomerantz R, Zhang C, Arunachalam S, Gao L . The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424(6944):94-8. PMC: 1350966. DOI: 10.1038/nature01707. View

14.

Vilcek J . Novel interferons. Nat Immunol. 2002; 4(1):8-9. DOI: 10.1038/ni0103-8. View

15.

Jordan W, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G . Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2006; 8(1):13-20. DOI: 10.1038/sj.gene.6364348. View

16.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

17.

Zhou L, Wang X, Wang Y, Zhou Y, Hu S, Ye L . Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience. 2009; 159(2):629-37. PMC: 2650740. DOI: 10.1016/j.neuroscience.2008.12.036. View

18.

Kuhl B, Cheng V, Wainberg M, Liang C . Tetherin and its viral antagonists. J Neuroimmune Pharmacol. 2011; 6(2):188-201. PMC: 3087111. DOI: 10.1007/s11481-010-9256-1. View

19.

Witte K, Gruetz G, Volk H, Looman A, Asadullah K, Sterry W . Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009; 10(8):702-14. DOI: 10.1038/gene.2009.72. View

20.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst S, Otte J . IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005; 289(5):G960-8. DOI: 10.1152/ajpgi.00126.2005. View